2169919-21-3

2169919-21-3 structure

Name: SNDX-5613
Chemical Name: SNDX-5613
CAS Number: 2169919-21-3
Molecular Formula: C₃₂H₄₇FN₆O₄S
Molecular Weight: 630.82
Catalog: Signaling Pathways Epigenetics Epigenetic Reader Domain
Create Date: 2020-06-01 20:27:52
Modify Date: 2024-01-06 16:08:08
SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].

Name	SNDX-5613

Description	SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain
Target	Menin-MLL[1]
In Vivo	SNDX-5613 shows in vivo plasma IC50 of 53 nM. SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].
References	[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).